In order to determine the influence of HA-1 minor histocompatibility antigen mismatch on BMT outcome, we analyzed a pool of 94 thalassemic transplanted patients all selected for the presence of HLA-A * 0201 allele. The HA-1 typing was performed using SSP analysis. All the patients received bone marrow from HLA-identical MLC nonresponsive siblings. As graft-versus-host-disease (GVHD) prophylaxis, all patients received cyclosporin and short methotrexate. Grades II-IV GVHD occurred in five (33.3%) of the 15 patients with recipient HA-1 disparity compared with 14 (17.7%) of the 79 patients without HA-1 disparity. Despite the higher incidence of acute graft-versus-host-disease (aGVHD) in the group of patients with HA-1 incompatibility, these data were not statistically significant. However, it was interesting to observe that no GVHD developed in any of the 15 cases in which the recipient was HA-1 negative and the donor HA-1 positive.
Introduction
In recent years, allogeneic marrow transplantation has become a habitual curative approach for many hematological malignant and nonmalignant diseases. However, acute graft-versus-host-disease (aGVHD) is one of the main complications after BMT, the incidence of severe grade ranging, even in HLA-identical transplants, from 20 to 50%, depending on the disease and the type of immunosuppressive prophylaxis. 1 Bone marrow transplantation from HLA-identical siblings has been increasingly adopted for the treatment of thalassemia. 2 Among the over 950 thalassemic patients transplanted in our BMT Center, the overall incidence of grades II-IV and III-IV aGVHD is 26.9 and 13.5%, respectively. 3 Risk factors associated with the onset of aGVHD are: patient age less than 4 years old, male patient sex, and GVHD prophylaxis.
The potential clinical significance of minor histocompatibility antigens (mHag) has recently been the object of numerous studies.
Mismatching for mHag-HA1 has been associated with an increased risk of aGVHD after HLA-identical marrow transplantation 4 and the emergence of donor-derived HA1 specific cytotoxic T lymphocytes (CTLs) in different cohorts of transplanted patients with GVHD suggests an immunodominant behavior of HA-1. 5 This minor histocompatibility antigen is a nonapeptide encoded by the KIAA0223 gene, located on chromosome 19, which has two known alleles, named HA- 6 However, the real influence of this mHag is still controversial and a recent paper reporting data on 613 HLA-A2 donor-recipient pairs showed no statistically significant association between HA-1 disparity and a higher incidence of aGVHD. 7 Typing of HA-1 mHag could be of particular relevance for patients with a nonmalignant disease such as thalassemia, where BMT-related risks need to be carefully considered. The aim of this study was to investigate if mHag HA-1 may be responsible for aGVHD in thalassemic patients undergoing HLA-identical BMT.
Materials and methods

Patients selection
We examined 94 thalassemic recipients of unmodified bone marrow, transplanted at the BMT Center of Pesaro, and their genotypically HLA-identical donors.
The donor-recipient pairs were selected according to the presence of HLA-A * 0201. There were 52 males and 42 females with a median age of 11.3 years (range 1-27 years). In total, 23 patients were adults while 71 were children (agep16).
The diagnosis and the severity of aGVHD were defined according to the Seattle Transplant Team criteria. 8 All patients received methotrexate (MTX) and cyclosporin (CsA) for GVHD prophylaxis and had either grades 0-I (75 patients-79.8%) or grades II-IV (19 patients-20.2%) aGVHD.
HA-1 genotyping
Genomic DNA was isolated from peripheral blood with Qia Amp DNA Mini Kit according to the manufacturer's instructions. As described previously, 9 genomic DNA was amplified by allele-specific PCR using two different primer sets designed so that each contained a common primer and specific primers for the HA-1 H/R allele. PCR reactions, containing 100 ng of genomic DNA and 20 pmol of each primer, were subjected to denaturation at 941C for 2 min followed by 10 cycles at 941C for 10 s and 651C for 60 s and 20 cycles at 941C for 10 s, 611C for 50 s, 721C for 30 s. Amplification with primer set 1 gave a 191 bp fragment, while primer set 2 resulted in a 331 bp fragment.
Typing of HLA-A * 0201
All the donor/recipient pairs were selected as HLA-A 0 -GGACGGGGAG ACACGGAAAG) was performed as already described. 10 
Statistical analysis
The statistical significance of the differences between groups was calculated using w 2 test with Yates's correction. Odds ratios (OR) and 95% confidence intervals were calculated according to Woolf's formula.
Results
In this study we analyzed 94 thalassemic patients receiving an HLA-identical sibling BMT in order to evaluate if HA-1 disparity could be associated with an increased risk of aGVHD. All the HLA-A * 0201-positive patients received both MTX and CsA for GVHD prophylaxis. Table 1 shows the distribution of the HA-1 genotypes among the 188 individuals tested. The HA-1 H allele frequency was 0.343, while the HA-1 R allele frequency was 0.657. The HA-1 H phenotype frequency of 0.564 was slightly lower than the values found by others.
11,12
When we evaluated the incidence of aGVHD among the different sibling pairs phenotype combinations, we did not find any significant difference. Strikingly, we found no evidence of aGVHD in any of the HA-1-negative patients transplanted with an HA-1-positive donor ( 13, 14 Further investigation restricted to the smaller group of nine patients with aGVHD grades III-IV confirmed the lack of correlation between recipient HA-1 incompatibility and development of severe aGVHD (data not shown).
Considering our group of patients almost as a pediatric group, we studied the influence of HA-1 mismatch on the incidence of aGVHD according to age (416o). The results of the two separate analysis showed the same tendency as the overall results. The OR for the adult and the pediatric groups were 2.33 (95% CI: 028-19.22) and 2.18 (95% CI: 0.48-9.86), respectively (Table 4) . Recipient mHag-HA1 S Nesci et al
Discussion
GVHD is one of the major complications of allogeneic bone marrow transplantation even when the donor and the recipient are HLA-identical siblings. It has been suggested that inheritable differences other than HLA, generally referred to as mHag, may be responsible for these complications.
mHag are encoded by polymorphic loci that are independent of each other and independent of HLA. In patients receiving an HLA-identical transplant, mHag disparities may generate anti-host CTLs and T helper cells with specific activity for mHag, thereby enhancing the afferent phase of GHVD.
Goulmy et al 4 first observed an association between the presence of a mismatch for the HA-1 mHag and the occurrence of GVHD in leukemic patients undergoing HLA-identical BMT. 4 Subsequent studies found a trend towards a higher risk of grades II-IV aGVHD in recipients mismatched for HA-1, but failed to confirm a statistically significant association with the development of acute or chronic GVHD. 7, 13, 14 Moreover, most reports on the correlation between GVHD and the disparity for both HA-1 and other mHag have been restricted to malignant diseases so far.
In our study, we performed HA-1 genomic typing in a group of 94 HLA-A * 0201 thalassemic patients undergoing BMT from an HLA-identical donor.
The distribution of GVHD and graft rejection was similar in the four phenotype groups, but we detected moderate or severe grade GVHD in 33.3% of the patients with HA-1 disparity compared with 17.7% of the nonmismatch group. These data showed a trend towards a higher occurrence of aGVHD in the group of pairs with recipient HA-1 incompatibility, but they did not reach the statistical significance reported by Goulmy et al 4 In other words, our current results do not exclude the possibility that HA-1 incompatibility can account for the risk for GVHD, but the OR for any such association is likely to be less than 2.3. This value is in good accordance with those found by most of the latest recent studies. 7, 14 It is remarkable to notice that the group in Leiden found a significant association between HA-1 mismatch and GVHD in adults, but not in children. One hypothesis to account for the absence of such a correlation in our group of donor-recipient pairs could be the considerable number of pediatric thalassemic patients. Also, these results could reflect differences in the pathophysiology of the disease (thalassemia vs leukemia) and in GVHD prophylaxis.
However, in the light of both the low frequency of HA-1 disparity (15.9%) and the low incidence of aGVHD grades II-IV (20.2%), it remains very difficult to establish a significant correlation.
In conclusion, this study shows that aGVHD is not significantly affected by HA-1 mismatch in thalassemictransplanted patients and does not support the idea that prospective genomic typing for the HA-1 alleles might improve donor selection. However, we believe that it could be useful as an additional test if more than one HLAidentical donor is available for BMT. Further studies on a larger group of transplants are probably necessary to deepen our understanding of the real influence of HA-1 and other mHag on BMT outcome in thalassemia. 
